brexucabtagene autoleucel
gilead
['brexu-cel', 'kitepharma']
the ages of the 76 patients treated with s brexu-cel ranged from 18 years to 81 years (median, 44). #asco23 read more: 
CGTLive™ delivers quality and relevant information to healthcare professionals on cell, gene, regenerative, and engineered medicines to ultimately improve care.